Important note

This AI stock analysis for Black Diamond Therapeutics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Black Diamond Therapeutics - AI Stock Analysis

Analysis generated September 13, 2025

Black Diamond Therapeutics is an innovative biotechnology company focused on discovering and developing precision medicines for genetically defined cancers with limited treatment options. The company employs its proprietary Mutation Allostery Pharmacology (MAP) platform to identify and target new drug candidates. Specializing in precision oncology, Black Diamond Therapeutics aims to address significant unmet medical needs and provide breakthrough treatments for cancer patients.

Fundamental Analysis

Black Diamond Therapeutics' financial performance for the last quarter illustrates some concerning trends. The revenue for the last quarter was $0, representing a 100% decrease compared to the previous quarter. This zero revenue is consistent with the same quarter last year, indicating potential issues in revenue generation or reliance on non-revenue milestones.

Net income for the last quarter stood at -$11M, marking a decrease of 118.68% from the previous quarter, indicating rising expenses or investment activities. Year-over-year, net income has improved by 46.95%, suggesting some positive development over the long term.

EBITDA was -$13M for the last quarter, representing a 124.57% decline compared to the previous quarter. However, compared to the same quarter last year, there is a year-over-year increase of 39.12%, suggesting some underlying operational improvements.

The current Price-to-Earnings (P/E) ratio is 14.04, which is generally within a normal range and indicates that the stock is neither overvalued nor undervalued based on its earnings.

Technical Analysis

Today's stock price is $3.25, up 17.33% from a month ago, indicating strong short-term momentum. However, the stock has declined by 47.50% over the past year, raising some concerns about long-term performance.

The Simple Moving Average (SMA) over the last 10 days is currently $3.11, slightly higher than the previous 10-day SMA of $3.07, signaling a potential short-term upward trend. The Relative Strength Index (RSI) is at 12.9, indicating that the stock might be oversold and potentially poised for a bullish rebound.

Alternative Data Analysis

According to job boards, Black Diamond Therapeutics has had 0 open positions recently, a stable status that indicates no immediate expansion or contraction. However, internal employee sentiment is low, with only 26% of employees having a positive outlook on the company.

Web traffic data shows that the company’s website attracts around 3,000 visitors monthly, a decline of 25% over recent months. This trend might signal waning interest or engagement from customers.

Additionally, the AltIndex AI score for Black Diamond Therapeutics is 45, which falls into the 'hold' category. This score integrates fundamental, technical, and alternative data points, providing a cautious but steady outlook.

Conclusion and Recommendation

In summary, Black Diamond Therapeutics shows mixed signals across different metrics. While short-term technical indicators suggest some upward momentum, long-term performance, declining web traffic, and poor internal sentiment are points of concern. On the fundamentals side, there are significant issues with revenue generation, though some long-term operational improvements are evident.

Given the confluence of these factors, along with the AltIndex AI score of 45 recommending a 'hold,' it may be prudent for current investors to maintain their positions while new investors might want to adopt a cautious approach until further positive signals emerge or additional data becomes available.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.